Zhitong Finance App News, Shenlian Biology (688098.SH) issued an announcement to evaluate the efficacy, safety, pharmacokinetics and pharmacokinetics of UB-221 as an additive therapy for chronic spontaneous urticaria (CSU) with a Class 1 biopharmaceutical UB-221 injection developed independently by the company Sun Company, Yangzhou Shizhiyuan Biotechnology Co., Ltd. (hereinafter referred to as “Shizhiyuan”). “Science” has reached a major end , and achieved positive top-line results.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Shenlian Biology (688098.SH) issued an announcement to evaluate the efficacy, safety, pharmacokinetics and pharmacokinetics of UB-221 as an additive therapy for chronic spontaneous urticaria (CSU) with a Class 1 biopharmaceutical UB-221 injection developed independently by the company Sun Company, Yangzhou Shizhiyuan Biotechnology Co., Ltd. (hereinafter referred to as “Shizhiyuan”). “Science” has reached a major end , and achieved positive top-line results.